Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.

NCT04116541 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT04116541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04116541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Recruiting
Start date
January 28, 2020
Completion date
October 31, 2027
Enrollment
455 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor